Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study
International Journal of Dermatology · 2025-07 · 64 (7) · 1242-1245
DOI: 10.1111/ijd.17732 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Dermatology, online erschienen am 21.03.2025. Verfasst von Isotta Giunipero di Corteranzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Alopecia Areata, Azetidines, Sulfonamides, Pyrazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Introduction
In adults, baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the first globally approved treatment for severe alopecia areata (AA). Its efficacy and safety were established in phase III trials, but real‐life evidence remains limited.
Objective
Our aim was to evaluate the real‐life safety profile of baricitinib over 48 weeks in a clinical setting.
Methods
A prospective observational study was conducted on 87 adult patients with severe AA at the University Hospital of Turin. Patients were treated with baricitinib at doses of 2 or 4 mg daily and were evaluated at baseline, 12, 24, 36, and 48 weeks. Adverse events (AEs) were carefully monitored, and disease severity was measured using the Severity of Alopecia Tool (SALT) score.
Results
The cohort consisted of 71% females, with a mean age of 42 years and a mean baseline SALT score of 76.9. Baricitinib was generally well tolerated, with 20% of patients reporting AEs. The most common AEs were hypercholesterolemia (17%), hypertriglyceridemia (9.2%), and upper respiratory tract infections (5%). Two patients discontinued treatment due to neutropenia and recurrent infections. Most AEs were mild and manageable.
Conclusion
Baricitinib shows a favorable safety profile in real‐life clinical settings, aligning with findings from controlled clinical trials. The results support its use in routine clinical practice, though larger prospective studies are needed for further confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
ORCID-Profile: Isotta Giunipero di Corteranzo, Eleonora Bongiovanni, Stephano Cedirian, Luca Mastorino
Zitieren
APA
di Corteranzo, I. G., Bongiovanni, E., Cedirian, S., Starace, M., Piraccini, B. M., Mastorino, L., Quaglino, P., Ribero, S., & Gallo, G. (2025). Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study. International Journal of Dermatology, 64(7), 1242-1245. https://doi.org/10.1111/ijd.17732
Vancouver
di Corteranzo IG, Bongiovanni E, Cedirian S, Starace M, Piraccini BM, Mastorino L, et al. Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study. International Journal of Dermatology. 2025;64(7):1242-1245. doi:10.1111/ijd.17732
BibTeX
@article{diCorteranzo2025,
author = {di Corteranzo, Isotta Giunipero and Bongiovanni, Eleonora and Cedirian, Stephano and Starace, Michela and Piraccini, Bianca Maria and Mastorino, Luca and Quaglino, Pietro and Ribero, Simone and Gallo, Giuseppe},
title = {Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study},
journal = {International Journal of Dermatology},
year = {2025},
volume = {64},
number = {7},
pages = {1242--1245},
doi = {10.1111/ijd.17732}
}
EUVIMED